MX2010005786A - Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol. - Google Patents
Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol.Info
- Publication number
- MX2010005786A MX2010005786A MX2010005786A MX2010005786A MX2010005786A MX 2010005786 A MX2010005786 A MX 2010005786A MX 2010005786 A MX2010005786 A MX 2010005786A MX 2010005786 A MX2010005786 A MX 2010005786A MX 2010005786 A MX2010005786 A MX 2010005786A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- treatment
- alkyl
- compounds
- manufacture
- Prior art date
Links
- 229940122361 Bisphosphonate Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 abstract 1
- 208000007932 Progeria Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000013823 prenylation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical class OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen ácidos [(imidazol-1-il)-1-hidroxi-1-fosfono-etil]-fos fónicos sustituidos por alquilo de 2 a 5 átomos de carbono, así como métodos o procesos para su fabricación, su uso en la fabricación de formulaciones farmacéuticas, su uso en el tratamiento de enfermedades, métodos para utilizarlos en el tratamiento de enfermedades, formulaciones farmacéuticas que los abarcan, y/o los compuestos para utilizarse en el tratamiento de enfermedades. Los compuestos son capaces de inhibir la resorción ósea excesiva o inapropiada, y para el tratamiento de otras enfermedades que sean causadas por una prenilación excesiva de las proteínas objetivo, tales como síndrome de progeria de Hutchinson-Gilford. Los compuestos son de la Fórmula 1: (ver fórmula (I)) en donde uno de R1 y R2 es hidrógeno, y el otro es alquilo de 2 a 5 átomos de carbono que está ramificado o no ramificado, y que pueden estar en forma libre, o en la forma de un éster, y/o de una sal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07122016 | 2007-11-30 | ||
| PCT/EP2008/066245 WO2009068567A1 (en) | 2007-11-30 | 2008-11-26 | C2-c5-alkyl-imidazole-bisphosphonates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010005786A true MX2010005786A (es) | 2010-06-09 |
Family
ID=39154111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010005786A MX2010005786A (es) | 2007-11-30 | 2008-11-26 | Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7977323B2 (es) |
| EP (1) | EP2225252B1 (es) |
| JP (1) | JP5244917B2 (es) |
| KR (1) | KR20100092035A (es) |
| CN (1) | CN101835787A (es) |
| AR (1) | AR069437A1 (es) |
| AU (1) | AU2008328797B2 (es) |
| BR (1) | BRPI0819902A2 (es) |
| CA (1) | CA2701516A1 (es) |
| CL (1) | CL2008003545A1 (es) |
| CO (1) | CO6280421A2 (es) |
| CR (1) | CR11362A (es) |
| EA (1) | EA201000860A1 (es) |
| EC (1) | ECSP10010321A (es) |
| ES (1) | ES2386851T3 (es) |
| IL (1) | IL204657A0 (es) |
| MA (1) | MA31895B1 (es) |
| MX (1) | MX2010005786A (es) |
| NZ (1) | NZ584219A (es) |
| PE (1) | PE20091038A1 (es) |
| TN (1) | TN2010000138A1 (es) |
| TW (1) | TW200932248A (es) |
| WO (1) | WO2009068567A1 (es) |
| ZA (1) | ZA201001992B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2273980A2 (en) * | 2008-04-04 | 2011-01-19 | Novartis AG | Pharmaceutical composition with bisphosphonate |
| PT2459176T (pt) | 2009-07-31 | 2017-12-11 | Gruenenthal Gmbh | Método de cristalização e biodisponibilidade |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9290526B2 (en) | 2010-05-28 | 2016-03-22 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
| WO2011147038A1 (en) | 2010-05-28 | 2011-12-01 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| CN102659840B (zh) * | 2012-05-10 | 2013-08-14 | 苏州普瑞诺药物技术有限公司 | 咪唑双膦酸类化合物及其可药用盐及药物用途 |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| CN111225672B (zh) | 2017-10-16 | 2023-09-29 | 清华大学 | 甲羟戊酸通路抑制剂及其药物组合物 |
| CN112980809B (zh) * | 2021-03-17 | 2023-04-11 | 云南中烟工业有限责任公司 | 一种烟草法尼基焦磷酸合酶基因及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2038692T4 (es) | 1986-11-21 | 2012-02-10 | Novartis Ag | Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos. |
| ES2069424T3 (es) * | 1991-02-26 | 1995-05-01 | Procter & Gamble Pharma | Metodos para el tratamiento de la osteoporosis. |
| GB9324143D0 (en) | 1993-11-24 | 1994-01-12 | Schering Agrochemicals Ltd | Triazole phosphonate pesticides |
| GB0029018D0 (en) * | 2000-11-28 | 2001-01-10 | Strakan Group Plc | Dermatological formulations |
| GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| WO2006039721A2 (en) | 2004-10-08 | 2006-04-13 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| US8012949B2 (en) | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
| AU2007304205A1 (en) | 2006-10-05 | 2008-04-10 | Novartis Ag | Pharmaceutical compositions comprising bisphosphonates |
| US20100144751A1 (en) | 2007-03-28 | 2010-06-10 | Array Biopharma Inc. | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
-
2008
- 2008-11-26 ES ES08854485T patent/ES2386851T3/es active Active
- 2008-11-26 NZ NZ584219A patent/NZ584219A/en not_active IP Right Cessation
- 2008-11-26 EP EP08854485A patent/EP2225252B1/en active Active
- 2008-11-26 EA EA201000860A patent/EA201000860A1/ru unknown
- 2008-11-26 WO PCT/EP2008/066245 patent/WO2009068567A1/en active Application Filing
- 2008-11-26 MX MX2010005786A patent/MX2010005786A/es active IP Right Grant
- 2008-11-26 KR KR1020107014395A patent/KR20100092035A/ko not_active Application Discontinuation
- 2008-11-26 JP JP2010535369A patent/JP5244917B2/ja active Active
- 2008-11-26 AU AU2008328797A patent/AU2008328797B2/en not_active Ceased
- 2008-11-26 BR BRPI0819902-7A patent/BRPI0819902A2/pt not_active IP Right Cessation
- 2008-11-26 CN CN200880112351A patent/CN101835787A/zh active Pending
- 2008-11-26 US US12/323,696 patent/US7977323B2/en not_active Expired - Fee Related
- 2008-11-26 CA CA2701516A patent/CA2701516A1/en not_active Abandoned
- 2008-11-27 AR ARP080105163A patent/AR069437A1/es active IP Right Grant
- 2008-11-27 PE PE2008001990A patent/PE20091038A1/es not_active Application Discontinuation
- 2008-11-28 CL CL2008003545A patent/CL2008003545A1/es unknown
- 2008-11-28 TW TW097146484A patent/TW200932248A/zh unknown
-
2010
- 2010-03-19 ZA ZA2010/01992A patent/ZA201001992B/en unknown
- 2010-03-22 IL IL204657A patent/IL204657A0/en unknown
- 2010-03-26 TN TNP2010000138A patent/TN2010000138A1/fr unknown
- 2010-04-09 CR CR11362A patent/CR11362A/es unknown
- 2010-05-26 CO CO10063351A patent/CO6280421A2/es not_active Application Discontinuation
- 2010-05-31 MA MA32880A patent/MA31895B1/fr unknown
- 2010-06-30 EC EC2010010321A patent/ECSP10010321A/es unknown
-
2011
- 2011-05-26 US US13/116,671 patent/US20110224173A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CR11362A (es) | 2010-06-14 |
| JP2011504908A (ja) | 2011-02-17 |
| TW200932248A (en) | 2009-08-01 |
| IL204657A0 (en) | 2010-11-30 |
| ES2386851T3 (es) | 2012-09-03 |
| MA31895B1 (fr) | 2010-12-01 |
| CA2701516A1 (en) | 2009-06-04 |
| EP2225252A1 (en) | 2010-09-08 |
| CN101835787A (zh) | 2010-09-15 |
| US7977323B2 (en) | 2011-07-12 |
| AU2008328797A1 (en) | 2009-06-04 |
| NZ584219A (en) | 2012-03-30 |
| TN2010000138A1 (en) | 2011-09-26 |
| AR069437A1 (es) | 2010-01-20 |
| ECSP10010321A (es) | 2010-08-31 |
| US20090143337A1 (en) | 2009-06-04 |
| CL2008003545A1 (es) | 2009-06-05 |
| PE20091038A1 (es) | 2009-08-19 |
| CO6280421A2 (es) | 2011-05-20 |
| EP2225252B1 (en) | 2012-06-27 |
| ZA201001992B (en) | 2010-12-29 |
| AU2008328797B2 (en) | 2011-11-03 |
| US20110224173A1 (en) | 2011-09-15 |
| JP5244917B2 (ja) | 2013-07-24 |
| WO2009068567A1 (en) | 2009-06-04 |
| BRPI0819902A2 (pt) | 2015-05-19 |
| KR20100092035A (ko) | 2010-08-19 |
| EA201000860A1 (ru) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2010000138A1 (en) | C2-c5-alkyl-imidazole-bisphosphonates | |
| JO2885B1 (en) | Protein kinase inhibitors | |
| CY1121703T1 (el) | Ιατρικη χρηση του πολυμορφου a toy ibanδρονικου | |
| EA201690623A1 (ru) | Простациклиновые соединения, композиции и способы их использования | |
| NZ626505A (en) | Substituted pyrrolidine-2-carboxamides | |
| TN2009000509A1 (en) | Pyrazole carboxylic acid amides useful as microbiocides | |
| HRP20090076A2 (en) | Antiviral phosphinate compounds | |
| NZ613807A (en) | Phosphorus-containing group-substituted quinoline, its preparation process, medical composition containing the compound and application | |
| MA34804B1 (fr) | Compositions pesticides et procedes apparentes | |
| MX338980B (es) | Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9. | |
| RS53617B1 (en) | NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | |
| TW200640940A (en) | Ibandronate polymorph B | |
| NZ708529A (en) | Salt and solvates of a tetrahydroisoquinoline derivative | |
| CY1116168T1 (el) | Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 | |
| TW200716138A (en) | Stable active compound complex of salts of O-acetylsalicylic acid with basic amino acids and glycine | |
| MX2011012181A (es) | Composicion y metodo para controlar enfermedades de plantas. | |
| CO6660462A2 (es) | Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos | |
| MY164864A (en) | Indenone derivative and pharmaceutical composition comprising same | |
| UY32405A (es) | Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapia | |
| MX2012015100A (es) | Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina. | |
| UA110128C2 (uk) | Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди | |
| UA112556C2 (uk) | Інсектицидні похідні 2-метоксибензамідів | |
| MY147951A (en) | Crystalline potassium salt of lipoxin a? analogs | |
| EA201071183A1 (ru) | Безводная кристаллическая форма малеата орвепитанта | |
| MX2009007265A (es) | Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |